Navigation Links
Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
Date:1/24/2008

- U.S. Data Highlights Oral Xeloda versus Standard Infusional Chemotherapy

in Gastroesophageal and Colorectal Cancers -

NUTLEY, N.J., Jan. 24 /PRNewswire/ -- Roche announced today that a total of 33 abstracts involving its oral chemotherapy Xeloda(R) have been accepted for presentation at the 2008 Gastrointestinal Cancers Symposium in Orlando, Fla., from Jan. 25 to 27.

Five poster presentations based on U.S. data offer additional knowledge about Xeloda. Two of these U.S. abstracts compare the safety profile and usage patterns of therapy with oral Xeloda to that of intravenous fluorouracil (5-FU) therapy in gastroesophageal cancer. A second pair of U.S. abstracts evaluates the usage patterns and cost of Xeloda-based regimens against those of 5-FU-based regimens in colon and rectal cancer. The fifth U.S. abstract highlights preclinical efficacy and tolerability results of a novel Xeloda regimen (7/7, or 7 days on, 7 days off) using higher daily doses for the treatment of colorectal cancer.
-- Jan. 25, noon to 1 p.m., [Poster No. 72], A claims database analysis of

capecitabine treatment patterns in patients with gastroesophageal

cancer (GEC) (Presenter: Wasif Saif)

-- Jan. 25, noon to 1 p.m., [Poster No. 71], Capecitabine in patients with

gastroesophageal cancer (GEC): A claims database analysis of adverse

events (AEs) (Presenter: Wasif Saif)

-- Jan. 26, 5:30 to 6:30 p.m., [Poster No. 364], A claims database cost-

comparison analysis of capecitabine in the treatment of patients with

colon or rectal cancer (CRC) (Presenter: Edward Chu)

-- Jan. 27, 7 to 8 a.m., [Poster No. 465], Capecitabine use in patients

with colon and rectal cancer (CRC): A claims database analysis of

treatment (Presenter: Edward Chu)

-- Jan. 27, 7 to 8 a.m., [Poster No. A29], In vivo activity of traditional

vs. novel regimens of capecitabine (C) alon
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
2. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
3. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
4. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
5. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
6. Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)
7. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
8. Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting
9. Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium
10. Senesco Technologies Initiates Preclinical Studies for Cancer Target
11. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... -- Cumberland Pharmaceuticals Inc. ( CPIX) ... results for a patient preference study evaluating Kristalose ... laxative packaged as a crystalline powder, compared to ... the only prescription-strength laxative available in pre-measured powder ... a recent diagnosis of chronic constipation were administered ...
(Date:12/15/2009)... LAKE ZURICH, Ill., Dec. 15 Fenwal ... improving blood collection, separation, safety and availability, announced ... has granted Fenwal approval to market InterSol ® ... InterSol ® solution is a specialized product ... donated platelets, a vital blood component used to ...
(Date:12/15/2009)... 15 Reportlinker.com announces that ... available in its catalogue: ,, ... Analysis and Market Forecasts to 2015 ... ,, Systemic Lupus Erythematosus - Drug ... 2015 ,, Summary ,, ...
Breaking Medicine Technology:Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 2Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 3Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets 2Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 2Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 3Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 4Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 5Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 6Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 7Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 8Grand Opening 3A An Exercise Program for People Who Just Love To Dance 56635 1Grand Opening 3A An Exercise Program for People Who Just Love To Dance 56635 2AUDIO from Medialink and Pfizer 3A September is Pain Awareness Month 56632 1Announcing Sustainability in Packaging 2010 3A Strategies to make sustainability sustainable 13946 1Announcing Sustainability in Packaging 2010 3A Strategies to make sustainability sustainable 13946 2Announcing Sustainability in Packaging 2010 3A Strategies to make sustainability sustainable 13946 3
(Date:12/15/2009)... High levels of leptin associated with lower dementia risk, ... High blood levels of leptin, a hormone that regulates ... , "Hopefully, in 10 or 15 years this may ... reduce the risk of Alzheimer,s disease," said senior study ... at Boston University School of Medicine. "Or it may ...
(Date:12/15/2009)... but not delivered ,, WASHINGTON, Dec. 15 ... to ensure that healthcare reform does not override ... insurance companies in 37 states. ,, Prostate cancer ... the population and individuals who are identifiable as ... who have a family history of prostate cancer. ...
(Date:12/15/2009)... WHITE PLAINS, N.Y., Dec. 15 Team ... (LLS) groundbreaking charity sports training program, ... billion to support blood cancer research and patient ... has been the pre-eminent charity endurance sports training ... a marathon, half marathon, triathlon, 100-mile century cycle ...
(Date:12/15/2009)... 15 North American application activity for ... year-over-year, according to the MIB Life Index(SM) ... over the past three months have lifted year-to-date ... -1.6%, to flat at November,s close, -0.1%. ... in the benefits available from life insurance," says ...
(Date:12/15/2009)... can help older adults delay or reverse declining ... researchers at the Johns Hopkins Bloomberg School of ... the researchers found that seniors participating in a ... regions that support cognitive abilities important to planning ... the first of its kind to demonstrate that ...
Breaking Medicine News(10 mins):Health News:Fat Hormone May Protect Against Alzheimer's 2Health News:Fat Hormone May Protect Against Alzheimer's 3Health News:Men's Health Network Calls on Congress to Complete President Obama's Promise on Health Care Reform 2Health News:$1 Billion - For Charity! 2Health News:$1 Billion - For Charity! 3Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 2Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 3Health News:For older adults, participating in social service activities can improve brain functions 2
... 4 CryoCor, Inc. (Nasdaq:,CRYO), a medical device ... today the publication of a European study of ... purpose of the study was to evaluate the ... fibrillation and the effectiveness of an ablation,strategy focused ...
... study, 10 minutes of counseling helped people cut down on ... Even a little counseling on the dangers of alcohol abuse ... drinkers cut back by at least three drinks a week, ... a standard alcohol-use screening and counseling tool, then applied it ...
... 2 Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ... has received final approval from the,United States (U.S.) ... Drug Application (ANDA) for Ipratropium Bromide and Albuterol ... Watson,s Ipratropium Bromide and Albuterol Sulfate product ...
... Jan. 2 Barr Pharmaceuticals,Inc. (NYSE: BRL ... has received final approval from the U.S. Food ... Roche Laboratories Inc.,s KYTRIL(R),(granisetron hydrochloride) Tablets, 1mg (eq ... following the expiration of Roche,s patent on,December 28, ...
... KANSAS CITY, Mo. An estimated 750,000 hospitalized ... less than 30 percent of those leave the hospital ... the Jan. 3 issue of the New England Journal ... life-saving electrical shock (defibrillation) among hospitalized patients experiencing a ...
... free unique support channels, OWINGS MILLS, Md., Jan. ... that the Company is offering a special deal for,clients ... is,offering Pure Weight Loss clients $55 Off a Purchase ... http://www.puremedifast.com or by calling 800-692-1791., Medifast is ...
Other Medicine News:Health News:CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation 2Health News:CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation 3Health News:Brief Chat With ER Docs Can Curb Problem Drinking 2Health News:Watson Receives FDA Approval for Generic DuoNeb(R) 2Health News:Barr Receives Approval for Generic KYTRIL(R) Tablets, 1mg (Base) 2Health News:Barr Receives Approval for Generic KYTRIL(R) Tablets, 1mg (Base) 3Health News:For hospital patients, defibrillation delays mean lower survival 2Health News:Medifast Offers Stranded Pure Weight Loss Clients Unique Options 2Health News:Medifast Offers Stranded Pure Weight Loss Clients Unique Options 3
... chrome plated brass. Lamp supplied in ... coded systems worldwide are in general ... design give some variation in the ... well with other systems using locking ...
... Greenspec Laryngoscopes are a high quality fiberoptic ... bringing greater standardization to fiberoptic laryngoscopes. The ... and indicates it's ability to interconnect with ... light offers a cool, bright and focused ...
... vocal cords in even the most difficult cases. ... standard laryngoscope, Viewmax® does not require special training. ... to allow intubation whether you are faced with ... has a patented lens system that refracts the ...
... a unique fiberoptic laryngoscope blade that can ... sometimes needed during difficult intubations. The articulating ... blade to be raised by squeezing a ... operation produces a more complete exposure of ...
Medicine Products: